Live Evaluations

Topical Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Pediatricians and Dermatology Providers: PEDS23 Seminar-in-Depth

About

CME Seminar in Depth - May 6, 2023 10:25 AM EST

 Topical Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Pediatricians and Dermatology Providers 


This activity is supported by educational grants from Arcuits, Dermavant, and Incyte. 

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify challenges associated with the use of topical corticosteroids in patients with AD and psoriasis

  • 2Review nonsteroid topical agents for the treatment of AD and psoriasis

  • Discuss clinical considerations for dermatology providers and pediatricians who prescribe topical therapies to patients with AD and psoriasis

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Lawrence
Lawrence Eichenfield, MD

Professor of Dermatology and Pediatrics 
Vice-Chair, Department of Dermatology 
Chief, Pediatric and Adolescent Dermatology 
University of California, San Diego and Rady Children’s Hospital
San Diego, CA

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Lawrence Eichenfield, MD

Grant/Research Support: Abbvie, Arcutis, Castle, Dermavant, Galderma, Incyte, Pfizer, Target

Consultant: AbbVie, Almirall, Arena, Aslan, Dermavant, Eli Lilly, Forte, Galderma, Incyte,Krystal, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB and Ortho Derm

Speakers’ Bureau or Honoraria: Leo, Incyte, Pfizer, Regeneron, Sanofi

Ownership Interest: Forte (Board of Directors-options); Verrica: Board of Directors (options)

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved